India, Sept. 20 -- Teva Pharmaceutical Industries (TEVA) on Friday reported new real-world data showing that UZEDY helped patients with schizophrenia remain on treatment longer while reducing emergency room visits, hospitalizations, and overall healthcare costs compared with certain other long-acting injectable therapies. The findings were presented at Psych Congress 2026, in New Orleans.
Schizophrenia is a chronic mental health disorder that affects how people think, feel, and behave. Relapses often lead to psychiatric emergencies and hospitalizations, making long-term treatment adherence a key goal of care.
UZEDY is an extended-release injectable form of risperidone approved for the treatment of schizophrenia in adults and for the maint...